ロード中...
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge. We describe a 69-year-old never-smoking Japanese woman with postoperativ...
保存先:
| 出版年: | Respir Med Case Rep |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5805846/ https://ncbi.nlm.nih.gov/pubmed/29487786 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.12.005 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|